Loading...
•
Jun 30, 2022
Matinas BioPharma Q2 2022 Earnings Report
Matinas BioPharma reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $5.9 million, or $0.03 per share, for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities were approximately $38.5 million as of June 30, 2022, which is expected to fund planned operations through 2023.
75% of patients enrolled to date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline data in late Q3/early Q4 2022
FDA provides flexibility and clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected to Commence Q1 2023
Initial Scientific Advice and Positive Opinion on Orphan Drug Designation from EMA Provide Global Regulatory Alignment for MAT2203 in Key Commercial Regions
Company Remains in Discussions with BioNTech for Option to License the LNC Platform for mRNA on an Exclusive Basis